Table 1.

General prevalence of recorded drug exposures among the study sample

	Total		Death
Drug	N	%	N	%	p
ACE 2 antagonists
Captopril	9	0.7	1	1.1	0.7
Enalapril	270	20.7	54	20.0	.07
Cilazapril	1	0.1	0	0.0	0.7
Imidapril	1	0.1	0	0.0	0.7
Lisinopril	26	2.0	3	11.5	0.2
Ramipril	24	1.8	5	20.8	0.6
Fisinopril	1	0.1	0	0.0	0.7
ARB-II blockers
Losartan	111	8.5	27	24.3	0.9
Candesartan	7	0.5	2	28.6	0.7
Olmasertan	3	0.2	2	66.7	0.2
Valsartan	38	2.9	14	36.8	.07
Telmisartan	3	0.2	0	0.0	0.9
Irbesartan	4	0.3	1	25.0	0.9
Statins
Atorvastatina	80	6.1	20	25.0	0.9
Lovastatina	3	0.2	0	0.0	0.5
Rosuvastatina	5	0.4	1	20.0	0.7
Sinvastatina	136	10.4	29	21.3	0.4
Anticoagulant
Acenocumarol	83	6.4	18	21.7	0.5
Warfarina	4	0.3	2	50.0	0.2
Dabigatran	11	0.8	2	18.2	0.6
Edoxaban	8	0.6	1	12.5	0.4
Apixaban	53	4.1	10	18.9	0.3
Rivaroxaban	22	1.7	3	13.6	0.2
Dalteparina	1	0.1	0	0.0	0.8
Enoxaparina	10	0.8	1	10.0	0.3
Heparina	3	0.2	2	66.7	0.1
Platelet antiaggregant
AAS	328	25.1	93	28.4	.06
Ticagrelor	1	0.1	0	0.0	0.8
Clopidrogrel	60	4.6	16	26.7	0.7
Triflusal	5	0.4	3	60.0	.07
Inhaled corticosteroids
Budesonida	55	4.2	10	18.2	0.3
Beclometasona	46	3.5	11	23.9	0.9
Fluticasona	13	1.0	1	7.7	0.2
Fludrocortisona	1	0.1	0	0.0	0.8
Oral corticosteroids
Deflazacort	2	0.2	1	50.0	0.4
Prednisona	10	0.8	2	20.0	0.6
Prednisolona	41	3.1	14	34.1	0.1
Metilprednisolona	30	2.3	13	43.3	0.02
Dexametasona	9	0.7	0	0.0	0.1
Vitamine D derivatives (overall)	252	19.3	45	18.8	0.04